Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Mai 2022 10:00 ET | Quelle: Genmab A/S

Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress

Media Release Copenhagen, Denmark, May 12, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a variety of patient...
11. Mai 2022 11:01 ET | Quelle: Genmab A/S

Genmab Announces Financial Results for the First Quarter of 2022

May 11, 2022 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2022 Highlights DARZALEX® net sales as reported by Johnson & Johnson increased 36% compared to the first...
19. April 2022 06:29 ET | Quelle: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022

Company Announcement Net sales of DARZALEX® in the first quarter of 2022 totaled USD 1,856 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. COPENHAGEN, Denmark;...
13. April 2022 17:25 ET | Quelle: Genmab A/S

Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next stepsData from the clinical trial...
07. April 2022 19:44 ET | Quelle: Genmab A/S

Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement

Company Announcement COPENHAGEN, Denmark; April 8, 2022 – Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with...
29. März 2022 14:34 ET | Quelle: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; March 29, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
29. März 2022 14:29 ET | Quelle: Genmab A/S

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; March 29, 2022 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2022, the Company’s Board of Directors met to...
29. März 2022 09:15 ET | Quelle: Genmab A/S

Passing of Genmab A/S’ Annual General Meeting

Company Announcement At Genmab A/S’ Annual General Meeting held today March 29, 2022, the Annual Report for 2021 was approvedDischarge was given to the Board of Directors and the Executive Management...
14. März 2022 08:47 ET | Quelle: Genmab A/S

Genmab Announces the Nomination of a New Member of the Company’s Board of Directors

Company Announcement Genmab’s Board of Directors proposes that Elizabeth O’Farrell is elected as a new member of the Board of Directors COPENHAGEN, Denmark; March 14, 2022 – Genmab A/S (Nasdaq:...
08. März 2022 07:31 ET | Quelle: Genmab A/S

Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma

Media Release COPENHAGEN, Denmark; March 8, 2022 Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational...

Vorherige Seite

Nächste Seite